Fundraising Fox

Atavistik Bio

3 known investors

atavistikbio.com ↗

Atavistik Bio is a clinical-stage biotechnology company developing allosteric small-molecule therapeutics that selectively modulate disease-causing proteins. Its pipeline includes ATV-1601, an oral AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia, and a JAK2V617F mutant-selective inhibitor for myeloproliferative neoplasms.

BiotechHealthtech

Investors · 3

Nextech InvestZurich · $648K – $3.2M
The Column GroupSan Francisco · $30M
Lux CapitalreportedNew York · $100K – $100M

Funding

SEC filings, press & company announcements

$120M disclosed across 1 of 2 rounds · 2025–2026

  • Undisclosed amountSeries B ExtensionMar 2026
    Source ↗
  • $120MSeries B FinancingDec 2025 · 2 sources
    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

New funding, new jobs: 4 biotechs hiring after series B raises - BioSpacebiospace.com · Jul 2026Atavistik Bio Closes $40 Million Series B Extension for Advancement of its Pipeline Bringing Total Round Proceeds to $160 Millionglobenewswire.com · Mar 2026Fierce Biotech Fundraising Tracker '25: Atavistik adds $120M; Syneron Bio secures new fundsfiercebiotech.com · Dec 2025Atavistik Bio Raises $120 Million Series B | citybizcitybiz.co · Dec 2025Atavistik Bio Raises $120 Million Series B Financing to Advance the Development of Selective Allosteric Small Molecule Therapeutics for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and Myeloproliferative Neoplasms (MPNs)globenewswire.com · Dec 2025Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeuticsglobenewswire.com · Dec 2023

Frequently asked questions

What does Atavistik Bio do?
Atavistik Bio is a clinical-stage biotechnology company developing allosteric small-molecule therapeutics that selectively modulate disease-causing proteins. Its pipeline includes ATV-1601, an oral AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia, and a JAK2V617F mutant-selective inhibitor for myeloproliferative neoplasms.
Who are Atavistik Bio's investors?
Atavistik Bio's investors include Nextech Invest, The Column Group, Lux Capital.
How much funding has Atavistik Bio raised?
Atavistik Bio has disclosed $120M raised across 1 of its 2 known rounds.